Oxford BioDynamics adds Vulpes co-founder Diggle to board as it expands precision diagnostics

The latest announcement is out from Oxford BioDynamics ( (GB:OBD) ).

Oxford BioDynamics, a precision clinical diagnostics group listed on AIM, develops proprietary EpiSwitch 3D genomics-based tests such as the EpiSwitch PSE prostate cancer screen and EpiSwitch CiRT immuno-oncology response assay. The company operates from hubs in the UK, US and Malaysia and is broadening its test pipeline across oncology, neurology, inflammation, hepatology and animal health to support more personalized treatment decisions.

The company has appointed investor and life sciences specialist Martin Diggle as a non-executive director, nominated by major shareholder Vulpes Investment Management to replace outgoing director Stephen Diggle. His capital markets and sector experience, including previous board roles at several biotech firms, is expected to strengthen Oxford BioDynamics’ governance and investor alignment as it seeks to scale its diagnostics portfolio and consolidate its position in the precision medicine market.

Spark’s Take on OBD Stock

According to Spark, TipRanks’ AI Analyst, OBD is a Underperform.

The score is driven primarily by very weak financial performance (losses, high leverage, and deteriorating free cash flow). Technicals also lean bearish with the stock trading below major moving averages, partially offset by oversold RSI. Valuation remains constrained because negative earnings make P/E less informative and there is no dividend yield provided.

To see Spark’s full report on OBD stock, click here.

More about Oxford BioDynamics

Oxford BioDynamics is an international biotechnology and precision clinical diagnostics company focused on personalized healthcare, developing and commercializing blood-based tests for life-changing diseases. Its key products include the EpiSwitch PSE prostate cancer screening test, which significantly improves PSA accuracy, and the EpiSwitch CiRT test predicting responses to immuno-oncology checkpoint inhibitors, all built on its proprietary EpiSwitch 3D genomics biomarker platform.

The company is expanding its EpiSwitch-based test portfolio into oncology, neurology, inflammation, hepatology and animal health, supported by laboratories in Oxford, UK, a clinical lab in Maryland, US, and a reference facility in Penang, Malaysia. Listed on London’s AIM market under ticker OBD, Oxford BioDynamics serves global healthcare markets seeking more precise diagnostic and treatment-stratification tools.

Average Trading Volume: 16,942,444

Technical Sentiment Signal: Strong Sell

Current Market Cap: £8.15M

See more insights into OBD stock on TipRanks’ Stock Analysis page.